Emerging Treatments in HIV

Feature Article

Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV

Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV

Pitavastatin reduced low-density lipoprotein cholesterol to a greater extent than pravastatin with a similar safety profile in patients with HIV and dyslipidemia.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News

Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV

Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV

Pitavastatin reduced low-density lipoprotein cholesterol to a greater extent than pravastatin with a similar safety profile in patients with HIV and dyslipidemia.

Atazanavir/Ritonavir Plus Lamivudine is as Safe, Effective as Triple Therapy

Atazanavir/Ritonavir Plus Lamivudine is as Safe, Effective as Triple Therapy

Dual combination ART with atazanavir/ritonavir plus lamivudine demonstrated similar efficacy and safety as atazanavir/ritonavir plus 2 NRTIs at 48 weeks in the ATLAS-M trial.

Two HIV Studies Reinforce Guidelines Recommending TAF-Based Regimens

Two HIV Studies Reinforce Guidelines Recommending TAF-Based Regimens

Switching to TAF-based regimen was non-inferior to continuing TDF-based regimen in maintaining viral suppression.

Investigational 2-Drug HIV Regimen Showing Promise

Investigational 2-Drug HIV Regimen Showing Promise

Investigational combination of a once-daily 2-drug regimen of dolutegravir plus rilpivirine may be as effective as a 3- or 4-drug current antiretroviral regimen in HIV-1-infected patients.

Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

Viral loads can fluctuate over time depending on patients' access and response to HIV treatment, their medication adherence behavior, and care status.

Potential New Drug Option for Treatment-Naïve HIV-1 Patients

Potential New Drug Option for Treatment-Naïve HIV-1 Patients

The once-daily dosing doravirine appears to have similar efficacy and to be non-inferior to once-daily ritonavir-boosted darunavir (DRV+r) on a background of 2 NRTIs in HIV-1 treatment-naïve adults.

Investigational HIV Monoclonal Antibody Effective in Multiple Drug Resistant HIV-1

Investigational HIV Monoclonal Antibody Effective in Multiple Drug Resistant HIV-1

New phase 3 results were reported from a single arm, multicenter study evaluating the safety and effectiveness of ibalizumab in patients infected with multi-drug resistant HIV-1.

Stribild HIV Post-Exposure Prophylaxis Brings Higher Completion Rate

Stribild HIV Post-Exposure Prophylaxis Brings Higher Completion Rate

HIV PEP preferred regimen Stribild seems to be a good option for immunocompetent people without HIV infection due to the ease of use and tolerable adverse effect profile.

Trends in Cancer That Can Complicate HIV Management

Trends in Cancer That Can Complicate HIV Management

Cancer prevention efforts for patients with HIV should focus on smoking cessation and appropriate screening based on recommendations for the general population.

FDA Green Lights Odefsey for Treating HIV-1

FDA Green Lights Odefsey for Treating HIV-1

Combining emtricitabine and tenofovir alafenamide (Gilead Sciences) and rilpivirine (Janssen Sciences), Odefsey is Gilead's second tenofovir alafenamide-based regimen to receive FDA approval.

Sign Up for Free e-newsletters